Ascletis Pharma Inc. (HKEX: 1672), a China-based innovative R&D driven biotech company, announced on Wednesday that the United States Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ASC11, an oral inhibitor drug candidate aimed at 3-chymotrypsin like protease (3CLpro) for COVID-19.
The company has received approval to study the safety, tolerability and pharmacokinetics of ASC11 at various doses in healthy subjects co-dosed with 100mg ritonavir tablets. The company has produced both ASC11 and ritonavir tablets.
The Phase I clinical trial is to include three cohorts of healthy patients, including single- and multiple-dose escalation studies and a food impact study. The aim of the Phase one trial is to find the right dose to move into the pivotal Phase II/III in COVID-19 patients.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study